Compare · BSX vs STVN
BSX vs STVN
Side-by-side comparison of Boston Scientific Corporation (BSX) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $92.25B, about 18.8x STVN ($4.90B).
- Over the past year, BSX is down 39.2% and STVN is down 24.5% - STVN leads by 14.7 points.
- BSX has been more active in the news (3 items in the past 4 weeks vs 1 for STVN).
- BSX has more recent analyst coverage (25 ratings vs 20 for STVN).
- Company
- Boston Scientific Corporation
- Stevanato Group S.p.A.
- Price
- $62.06-5.52%
- $16.22-0.12%
- Market cap
- $92.25B
- $4.90B
- 1M return
- -11.05%
- +13.82%
- 1Y return
- -39.23%
- -24.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 1
- Recent ratings
- 25
- 20
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest STVN
- Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form 3 filed by new insider Santel Luciano
- SEC Form 3 filed by new insider Magistretti Elisabetta
- SEC Form 3 filed by new insider Flynn Karen
- SEC Form 3 filed by new insider Federici William J
- SEC Form 3 filed by new insider Spinazzi Alvise
- SEC Form 3 filed by new insider Morel Donald E Jr
- SEC Form 3 filed by new insider Stevanato Franco
- Amendment: SEC Form 3 filed by new insider Stevanato Sergio
- SEC Form 3 filed by new insider Lin Sue-Jean